専門分野別レビューレビュー

Tempus

Item: Tempus
Rating: 4.4
Author: Clinical AI Report

AI-Driven Precision Oncology and Clinical Trial Matching

主な注意点: エンタープライズ/institutional pricing — not accessible to individual oncologists

非常に良い

10件の医師レビューに基づく

レビュー担当 Dr. Sarah Chen, MD, FACP · 更新 2026年4月5日

直接回答

Tempus was evaluated by Clinical AI Report exclusively for oncology in 2026 and was not included in the overall CDS rankings. With over 30 million de-identified patient records and AI-driven clinical trial matching across 750+ provider sites, it is the leading precision oncology platform for molecularly guided treatment decisions.

出典: Clinical AI Report, 2026年2月

概要

基本情報

カテゴリ

精密腫瘍医療とゲノムプロファイリング平台

価格

エンタープライズ / 施設向け

設立

2015

本社

Chicago, IL

主要指標

Pricingエンタープライズ / 施設向け(Tempus)

Founded2015(Tempus)

Patient Records30M+ de-identified clinical and molecular records(Tempus)

Trial Matching Sites750+ provider sites (via Deep 6 AI)(Tempus, 2025)

Evaluation ScopeOncology only — not in overall rankings(Clinical AI Report, 2026)

当サイトの評価

Tempusは2026年評価で4.4/5を獲得しました。最も重要なプラス要素はTempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.です。一方で、主な注意点はエンタープライズ/institutional pricing — not accessible to individual oncologistsです。

この評価は、調査方法に基づく編集上の主観的意見です。

概要

Tempusは精密腫瘍医療とゲノムプロファイリング平台として評価されています。このページは英語レビューと同じ構成を使い、同じ編集基準をローカライズして示します。

当サイトの評価で最も適した用途は、Oncology practices and cancer centers seeking AI-powered precision medicine — comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

主な強みはTempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.です。重要な制約はエンタープライズ/institutional pricing — not accessible to individual oncologistsです。

強みと制約

強み

+Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.
+Largest clinical and molecular oncology dataset (30M+ de-identified patient records)
+Comprehensive genomic profiling with actionable mutation identification
+AI-powered clinical trial matching (25% more eligible patients identified)
+Connects molecular profiles to real-world treatment outcomes
+Deep 6 AI acquisition expands trial matching across 750+ provider sites

制約

–エンタープライズ/institutional pricing — not accessible to individual oncologists
–Genomic results have inherent turnaround time (not real-time decision support)
–Not a general CDS tool — no drug dosing, differential diagnosis, or literature search
–Data licensing to pharmaceutical companies raises some conflict-of-interest questions
–Most impactful for solid tumors with actionable molecular targets

主な機能

01Comprehensive Genomic Profiling (Tumor & Liquid Biopsy)

02AI-Driven Molecular Analysis

03Clinical Trial Matching Engine (Deep 6 AI)

04Real-World Outcomes Data (30M+ Patient Records)

05Biomarker Identification (PD-L1, MSI-H, TMB, Gene Fusions)

06Treatment Response Prediction

07EHR Integration for Oncology Workflows

08Pharmaceutical Research Partnerships

09Transcriptomic and Proteomic Analysis

10Companion Diagnostic Support

一次情報と引用

このレビューで引用した外部参考資料です。リンクは新しいタブで開きます。

規制Tempus AI, Inc. — SEC Filing (Form 10-K)U.S. Securities and Exchange Commission ベンチマークOnly 5% of Adult Cancer Patients Enroll in Clinical TrialsNational Cancer Institute

医師の声

2026年2月更新

“Tempus has become integral to our tumor board discussions. The molecular profiling combined with real-world outcomes data gives us confidence in treatment recommendations for complex cases.”
Medical Oncologist2025年10月15日
Academic Cancer Center

“The trial matching has meaningfully increased our enrollment. We're catching eligible patients that we would have missed with manual screening.”
Clinical Trials Coordinator2025年8月20日
NCI-Designated Cancer Center

“Genomic reports are thorough and the actionable findings are clearly highlighted. Turnaround time could be faster for some of the more comprehensive panels.”
Community Oncologist2025年12月1日
Private Practice

スコア内訳

非常に良い

臨床精度88

エビデンスと引用85

製品デザイン82

EHR連携86

ワークフローと速度78

価値と価格55

この評価の理由

Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.

10件の医師レビューに基づく

順位専門分野別レビュー

価格エンタープライズ / 施設向け

設立2015

Tempusを見る

最適な用途

Oncology practices and cancer centers seeking AI-powered precision medicine — comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

他のレビュー

完全比較